We found that Flu-IVIG treatment significantly increased HA-specific FcγRIIIa- and FcγRIIa-binding antibodies and resulted in greater NK cell activation compared with placebo in patients hospitalized with both B/Yamagata and A/H1N1 influenza. The gene discussed is FCGR3A; the disease is influenza.